Shire (NASDAQ:SHPG) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided EPS guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.02. The company issued revenue guidance of 15.4-15.9 billion, compared to the consensus revenue estimate of $15.47 billion.
Shire (NASDAQ:SHPG) opened at $132.67 on Wednesday. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $39,799.25, a PE ratio of 24.84, a PEG ratio of 0.71 and a beta of 1.41.
SHPG has been the subject of a number of recent research reports. Cowen set a $225.00 target price on Shire and gave the company a buy rating in a research note on Friday, January 5th. Zacks Investment Research raised Shire from a sell rating to a hold rating in a research note on Friday, October 27th. Cantor Fitzgerald reissued a buy rating and issued a $222.00 target price on shares of Shire in a research note on Friday, October 27th. Liberum Capital raised Shire from a hold rating to a buy rating in a research note on Tuesday, November 14th. Finally, ValuEngine raised Shire from a hold rating to a buy rating in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $212.50.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.